This Article Abstract Full Text (PDF) Methods Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, I. Articles by Koh, G. Y. Search for Related Content PubMed PubMed Citation Articles by Kim, I. Articles by Koh, G. Y. Related Collections Angiogenesis Growth factors/cytokines

(Circulation Research. 2000;86:952.)
© 2000 American Heart Association, Inc.

Cellular Biology

Angiopoietin-1 Induces Endothelial Cell Sprouting Through the Activation of Focal Adhesion Kinase and Plasmin Secretion

Injune Kim, Hwan Gyu Kim, Sang-Ok Moon, Soo Wan Chae, June-No So, Keum Nim Koh, Byung Cook Ahn, Gou Young Koh

From the National Creative Research Initiatives Center for Cardiac Regeneration and Institute of Cardiovascular Research (I.K., H.G.K., S.-O.M., S.W.C., J.-N.S., K.N.K., G.Y.K.) and Department of Ophthalmology (B.C.A.), Chonbuk National University School of Medicine, and Department of Biotechnology (J.-N.S.), Woosuk University, Chonju, Korea.

Correspondence to Gou Young Koh, MD, PhD, National Creative Research Initiatives Center for Cardiac Regeneration, Chonbuk National University School of Medicine, San 2-20, Keum-Am-Dong, Chonju, 560-180, Republic of Korea. E-mail gykoh{at}moak.chonbuk.ac.kr

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—Angiopoietin-1 (Ang1) is a strong inducer of endothelial cell sprouting, which is a first step in both angiogenesis and neovascularization. We examined the mechanisms underlying Ang1-induced cell sprouting using porcine pulmonary artery endothelial cells. Ang1 induced the nondirectional and directional migration of endothelial cells mediated through the Tie2 but not the Tie1 receptor. Ang1 induced tyrosine phosphorylation of p125^FAK, and this phosphorylation was dependent on phosphatidylinositol (PI) 3'-kinase activity. Ang1 induced the secretion of plasmin and matrix metalloproteinase-2 (MMP-2), which is inhibited by PI 3'-kinase inhibitors. Ang1 also induced the secretion of small amounts of proMMP-3 and proMMP-9 but not proMMP-1. Ang1 suppressed the secretion of tissue inhibitor of metalloproteinase-2 (TIMP-2), but not of TIMP-1. Addition of ₂-antiplasmin, a combination of TIMP-1 and TIMP-2, or PI 3'-kinase inhibitors inhibited Ang1-induced sprouting activity. Therefore, Ang1-induced sprouting activity in endothelial cells may be accomplished by cytoskeletal changes and secretion of proteinases and may be largely mediated through intracellular PI 3'-kinase activation.

Key Words: angiopoietin-1 • sprouting • p125^FAK • plasmin

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Angiopoietin (Ang)–1 and Ang2 have recently been identified as ligands of the endothelial cell–specific Tie2 receptor.^{1 2} In vivo analyses by targeted gene inactivation and transgenic overexpression suggest that Ang1 recruits and sustains periendothelial support cells, whereas Ang2 disrupts blood vessel formation in the developing embryo by antagonizing the effects of Ang1 on Tie2.^{2 3} Interestingly, transgenic overexpression⁴ or gene transfer⁵ of Ang1 increases vascularization in vivo. In vitro experiments have shown that Ang1 has specific effects on endothelial cells; it potently induces chemotactic response,⁶ network formation,⁷ and survival in apoptosis.^{8 9} Ang1 also causes sprouting of endothelial cells in fibrin gel, although it has no proliferative effect.^{10 11}

The sprouting of endothelial cells is an initial step in angiogenesis and neovascularization.^{12 13} Sprouting requires cell migration into the extracellular matrix beneath the basement membrane.^{12 13} Cell migration requires reorganization of the actin cytoskeleton.¹⁴ A member of the non–receptor protein tyrosine kinases, p125^FAK, plays a key role in regulating dynamic changes in actin cytoskeleton organization during migration and adhesion.¹⁵ p125^FAK is activated by tyrosine phosphorylation, which is induced by growth factors.¹⁶ Paxillin is a cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion and is associated with p125^FAK.¹⁷ Phosphorylation of p125^FAK produces simultaneous phosphorylation of paxillin.¹⁷ Endothelial cells release proteinases to degrade extracellular matrix for their migration during the sprouting process in vivo.^{18 19} One family of such enzymes is the matrix metalloproteinases (MMPs).²⁰ MMPs are secreted in a proenzyme form and require proteolytic cleavage for activation.^{21 22} MMPs are inhibited by endogenous tissue inhibitors of metalloproteinase (TIMPs), which form 1:1 complexes with MMPs.^{21 22} The balance between the levels of MMPs and TIMPs is a critical factor in regulating the breakdown of connective tissues by migrating cells.

In this report, we investigate the possible mechanisms of Ang1-induced sprouting in endothelial cells. Ang1-induced migration may occur through tyrosine phosphorylation of p125^FAK and paxillin. In addition, Ang1 induced the secretion of plasmin and increased the secretion ratio of MMP-2/TIMP-2. Therefore, we propose that Ang1-induced sprouting activity in endothelial cells may be accomplished by cytoskeletal changes and secretion of proteinases.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials and Cell Culture
The Ang1*, Ang2, soluble Tie1 receptor-Fc (rTie1-Fc), and soluble Tie2 receptor-Fc (rTie2-Fc) proteins were obtained from Regeneron Pharmaceuticals, Inc. Ang1* is a recombinant version of Ang1 with modified NH₂ terminus and mutated Cys²⁴⁵ that is easier to produce and purify. Mutation of Cys²⁴⁵ in Ang1, which is not shared between Ang1 and Ang2, does not alter its agonistic property.² Recombinant human vascular endothelial growth factor₁₆₅ (VEGF₁₆₅) was purchased from R&D systems. Phosphatidylinositol (PI) 3'-kinase inhibitors wortmannin and LY294002 were purchased from RBI, Inc. Recombinant human TIMP-1 and TIMP-2 were purchased from Fuji Chemical Industries. Media and sera were obtained from Life Technologies, Inc. Most other biochemical reagents were purchased from Sigma, unless otherwise specified. All cells used in this study were porcine pulmonary artery endothelial cells (PPAECs). PPAECs were prepared from porcine pulmonary arteries by collagenase digestion and maintained as previously described.¹¹

Sprouting Assay
The sprouting assay in PPAECs was performed as previously described.¹¹ Briefly, PPAECs were grown to confluence on microcarrier beads (diameter 175 µm; Sigma) and placed in a 2.5 mg/mL fibrinogen gel containing 2.0% heat-inactivated FBS and the indicated recombinant protein. Fibrin gels were incubated in DMEM with a daily addition of the same amount of recombinant protein. After 3 days, 2 independent, blinded investigators counted the number of sprouts with the use of an inverted microscope.

Nondirectional and Directional Migration Assays
For the nondirectional migration assay, the microcarrier bead migration method was used.²³ For the directional migration assay, the method using a modified Boyden chamber (Neuroprobe, Inc) was used.

p125^FAK and Paxillin Tyrosine Phosphorylation Assay
PPAECs were incubated in serum-free DMEM for 24 hours. Then, Ang1* was added at the indicated amounts and incubated for the indicated times. The phosphorylation status of immunoprecipitated protein was detected by Western blot analysis using anti-phosphotyrosine, anti-p125^FAK, or anti-paxillin antibody as previously described.¹¹

Measurements of Plasmin and MMPs in Culture Medium
Confluent PPAECs were incubated in serum-free and phenol red-free DMEM for 24 hours. After the cells were washed with fresh medium, control buffer, Ang1*, or VEGF was applied for the indicated times. Plasmin activities were measured in the media by fibrin-zymography and by a colorimetric assay according to the manufacturer’s protocol (Chromozym PL, Boehringer Mannheim). The actual amounts of the proforms of the MMPs (proMMPs), TIMP-1, and TIMP-2 were assayed with enzyme immunoassays according to the manufacturer’s protocol (Fuji Chemical Industries). The hydrolytic activities of MMP-2 and MMP-9 were measured by gelatin-zymography as previously described.²⁴

Statistics
Data are expressed as mean±SD. Statistical significance was tested using 1-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance was set at P<0.05.

An expanded Materials and Methods section is available online at http://www.circresaha.org.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Ang1*, but Not Ang2, Induces Sprouting in PPAECs
The placement of microcarrier beads onto a confluent monolayer of PPAECs for 2 to 3 days produces beads covered by a confluent monolayer of cells with 25 to 30 cells per bead. These beads were embedded in 3-dimensional fibrin gels and cultured. Daily addition of Ang1* (50 to 400 ng/mL) increased sprout formation in a dose-dependent manner, whereas Ang2 (50 to 400 ng/mL) did not increase sprout formation (Figures 1A and 1B). Koblizek et al⁶ obtained similar results with adrenal cortex–derived microvascular endothelial cells, although the magnitude of sprout formation was somewhat lower than ours.⁶ As a positive control, VEGF (1 to 10 ng/mL) increased sprout formation in a dose-dependent manner (Figures 1A and 1B). In general, the relative potency in sprouting formation produced by VEGF was higher than that produced by Ang1*.

View larger version (60K): [in this window] [in a new window]   Figure 1. Effect of Ang1*, Ang2, and VEGF165 on sprouting activity in PPAECs. Cells grown on microcarrier beads were placed in fibrin gels containing control buffer, Ang1* (200 ng/mL), Ang2 (200 ng/mL), or VEGF165 (10 ng/mL) and were incubated with daily supplementation with the same amount of recombinant protein. A, Representative phase-contrast photographs of sprouting activity. Note that more, thinner, and longer sprouts are formed in VEGF-treated beads than in Ang1*-treated beads, whereas only a few short sprouts are formed in control and Ang2-treated beads. Magnifications are x200. B, Quantification of the sprouting activities. Number of endothelial sprouts with length exceeding the diameter of the microcarrier beads (175 µm) per 50 microcarrier beads was counted after 3 days. Data are mean±SD from 5 experiments. *P<0.05 vs control.

Ang1*, but Not Ang2, Induces Nondirectional and Directional Migration for PPAECs Through Tie-2 Receptor Binding
When PPAEC-bearing microcarrier beads were placed onto gelatinized plastic dishes with control buffer for 20 hours, they yielded a basal level of nondirectional migration (40 to 45 cells per 10 beads; Figures 2A and 2B). The number of migrating cells increased with Ang1* stimulation in a dose-dependent manner. In contrast, Ang2 (50 to 400 ng/mL) did not produce any increase in nondirectional migration. Consistent with a previous report,⁷ Ang1*, but not Ang2, also induced directional (chemotactic) migration in a dose-dependent manner (Figure 2B). As a positive control, VEGF induced nondirectional and directional migration in a dose-dependent manner (Figure 2B). A 5-fold molar excess of rTie2-Fc, but not rTie1-Fc, almost completely blocked the nondirectional and directional migratory effects of Ang1* (Figure 2B).

View larger version (39K): [in this window] [in a new window]   Figure 2. Effects of Ang1*, Ang2, VEGF, and soluble Tie1 and Tie2 receptors in nondirectional and directional migratory activity in PPAECs. PPAECs were grown to confluence on microcarrier beads, and the beads were placed in gelatinized 24-well plates in medium containing 2.0% FBS and incubated for 20 hours to examine nondirectional migratory activity. A modified Boyden chamber was used to examine directional migratory activity. A, Representative phase-contrast photographs of non-directional migratory activity. Control buffer, Ang1* (200 ng/mL), Ang2 (200 ng/mL), or VEGF165 (10 ng/mL) was added. The beads were stained with Giemsa solution. More migrating cells can be seen around the surface of well in Ang1*- or VEGF-treated beads. B, Quantification of nondirectional (a and b) and directional (c and d) migratory activities. Various amounts of recombinant protein were added to the beads (a and c). Ang1* (200 ng/mL) and control buffer (C) or a 5-fold molar excess (2 µg/mL) of rTie1-Fc or rTie2-Fc was added to the beads (b and d). HPF indicates high-power field (x100). Data are mean±SD from 5 experiments. *P<0.05 vs control.

Ang1* Induces p125^FAK and Paxillin Phosphorylation
Because Ang1* has a migratory effect in endothelial cells, we examined whether Ang1* could stimulate tyrosine phosphorylation of p125^FAK and paxillin. Ang1* (200 ng/mL) induced p125^FAK and paxillin phosphorylation as early as 5 minutes and produced a maximal effect at 10 minutes (Figures 3A and 3B). These effects declined but continued to be higher than control levels at up to 30 to 60 minutes. The maximum mean increases in p125^FAK and paxillin phosphorylation were 3.6- and 2.6-fold, respectively. Ang1* induced p125^FAK and paxillin phosphorylation at 10 minutes in a dose-dependent manner (Figures 3A and 3B). Thus, the Ang1*-induced phosphorylation of p125^FAK and of paxillin occurred in the same time frame, and to a similar extent. In contrast, Ang2 (200 and 400 ng/mL) made no change in either p125^FAK or paxillin phosphorylation at 10 minutes after stimulation (data not shown).

View larger version (53K): [in this window] [in a new window]   Figure 3. Effect of Ang1* on p125FAK and paxillin phosphorylation in PPAECs. A, Top, Tyrosine-phosphorylated p125FAK (a and b) and paxillin (c and d). Bottom, Total amount of p125FAK (a and b) and paxillin (c and d). Cells were exposed to Ang1* for the indicated times and amounts and Western blotted. B, Densitometric analyses of the blots are presented as relative ratios of phosphoprotein/total protein. Ratio in the control is arbitrarily presented as 1. Data are mean±SD from 3 experiments. *P<0.05 vs control.

PI 3'-Kinase Inhibitors Suppress Ang1*-Induced Tyrosine Phosphorylation of p125^FAK and Migration
To examine the involvement of PI 3'-kinase in Ang1*-induced tyrosine phosphorylation of p125^FAK and migration in endothelial cells, we examined the effects of PI 3'-kinase inhibitors on Ang1*-induced p125^FAK phosphorylation at the peak time point (10 minutes) and migration. PPAECs were preincubated with wortmannin or the structurally unrelated synthetic PI 3'-kinase–specific inhibitor, LY294002. Wortmannin or LY294002 almost completely inhibited the Ang1*-induced p125^FAK tyrosine phosphorylation and nondirectional and directional migration (Figures 4 and 5).

View larger version (69K): [in this window] [in a new window]   Figure 4. Effect of PI 3'-kinase inhibitors on Ang1*-induced p125FAK tyrosine phosphorylation in PPAECs. Cells were pretreated for 30 minutes with wortmannin (WT, 30 nmol/L) or LY294002 (LY, 100 nmol/L). Then, cells were incubated with Ang1* (200 ng/mL) for another 10 minutes. Top, Tyrosine-phosphorylated p125FAK. Middle, Total amount of p125FAK. Bottom, Fold induction of phosphorylated p125FAK/total p125FAK, comparing Ang1* treatment with control. Data are mean±SD from 3 experiments.

View larger version (31K): [in this window] [in a new window]   Figure 5. Effect of PI 3'-kinase inhibitors on Ang1*-induced nondirectional (A) and directional (B) migration activity. PPAECs were grown to confluence on microcarrier beads, which were then placed in gelatinized 24-well plates in medium containing 2.0% FBS with addition of buffer, Ang1* (200 ng/mL), alone or with wortmannin (WT, 10 nmol/L) or LY294002 (LY, 30 nmol/L). Cells were incubated for 20 hours, and then the number of migrating cells per 10 beads was counted. A modified Boyden chamber was used to examine directional migratory activity in the absence and presence of wortmannin or LY294002. Data are mean±SD from 5 experiments. *P<0.05 vs control; #P<0.05 vs Ang1* only.

Ang1* Induces Plasmin and MMP Secretion but Suppresses TIMP-2 Secretion
Because of the ability of Ang1 to induce cells to sprout in fibrin gels, we examined whether Ang1* causes plasmin secretion from PPAECs. Addition of Ang1* (200 ng/mL) or VEGF (10 ng/mL) produced 3.5- or 4.8-fold increases, respectively, in plasmin secretion for 3 hours compared with addition of control buffer (Figure 6A). The plasmin secretion was confirmed by fibrin zymography (Figures 7A and 7B). Culture medium from Ang1*- or VEGF-treated cells clearly had increased 85-kDa fibrinolytic bands compared with the cells treated with buffer alone (Figure 7A). This effect was still observed in cell media collected 24 hours after treatment (Figure 7A).

View larger version (35K): [in this window] [in a new window]   Figure 6. Effect of Ang1* and VEGF on secretion of plasmin (A), proMMPs (B), and TIMPs (C) in the absence and presence of PI 3'-kinase inhibitors in PPAECs. Cells were incubated in serum-free and phenol red-free DMEM for 24 hours. Control buffer (Co or Cont), Ang1* (200 ng/mL), or VEGF (10 ng/mL) was added to 0.5 mL of the same culture medium, cells were incubated for 3 hours, and media were assayed. Control buffer (C), wortmannin (W, 10 nmol/L) or LY294002 (L, 30 nmol/L) was pretreated 30 minutes before Ang1* or VEGF addition. Data are mean±SD from 5 or 6 experiments. *P<0.05 vs control; #P<0.05 vs Ang1*; P<0.05 vs VEGF only.

View larger version (35K): [in this window] [in a new window]   Figure 7. Zymographic analysis of the secretion of plasmin and MMPs in culture medium of PPAECs. Cells were incubated in serum-free and phenol red-free DMEM for 24 hours. Control buffer (C), Ang1* (A) (200 ng/mL), or VEGF (V) (10 ng/mL) was added to 0.5 mL of same culture medium in the absence and presence of control buffer and wortmannin (W, 10 nmol/L) and incubated for the times indicated. A, Fibrin zymography (a) and gelatin zymography (b). Tenfold concentrated sample (5 µL) was loaded. Lane S contains standards of plasmin, the proforms of MMP-9 (pMMP9) and MMP-2 (pMMP2), and the active form of MMP-2 (aMMP2). Lanes AW and VW indicate that the media were taken from the cells treated with Ang1 or VEGF with wortmannin. Unknown indicates unknown nature of gelatinolytic band. Molecular weight markers (open arrowheads, right) were used to estimate molecular masses. B, Densitometric analyses of graphs are presented as the relative ratio of induction of plasmin (a) or MMPs (b) by addition of Ang1* or VEGF. The plasmin or proMMP2 secretion by addition of control buffer for 3 hours is arbitrarily presented as 1. Data are mean±SD from 4 experiments. nd indicates nondetectable. *P<0.05 vs control buffer; #P<0.05 vs Ang1*; P<0.05 vs VEGF only.

Preliminary enzyme immunoassay showed that the culture media from PPAECs and other endothelial cells contained marked amounts of proMMP-2, whereas proMMP-1, proMMP-3, and proMMP-9 levels were low or undetectable (data not shown). Addition of Ang1* (200 ng/mL) or VEGF (10 ng/mL) for 3 hours produced 2.2- or 3.3-fold increases, respectively, in proMMP-2 secretion, compared with control buffer (Figure 6B). Although Ang1* or VEGF produced a significant induction of proMMP-3 and proMMP-9 secretion, their increased amounts were low (Figure 6B). Neither Ang1* nor VEGF induced proMMP-1 secretion (Figure 6B). The profiles of MMP-2 and MMP-9 in the media were semiquantitatively assayed by gelatin zymography. Consistent with the results obtained from the enzyme immunoassays, gelatin zymography revealed that proMMP-2 secretion (68 kDa) was dominant (Figure 7A). Ang1* or VEGF produced 1.6- or 1.8-fold induction, respectively, of proMMP-2 secretion in the media at 3 hours (Figures 7A and 7B). At 24 hours after Ang1* or VEGF addition, the similar pattern of proMMP-2 secretion was observed (Figures 7A and 7B). Higher size (74 kDa) of gelatinolytic bands were observed in the media at 3 hours and were increased at 24 hours. Addition of Ang1* or VEGF induced these gelatinolytic activities similarly with patterns that resembled proMMP-2. In addition, increased proMMP-9 (92 kDa) and active MMP-2 (62 kDa) secretions were detected, although their amounts were low (Figures 7A and 7B). Addition of Ang1* or VEGF for 3 hours produced 45% or 60% suppression in the basal secretion of TIMP-2 (Figure 6C). However, the basal secretion of TIMP-1 was low, and the level was not changed by treatment with either Ang1* or VEGF.

We examined the effect of PI 3'-kinase inhibitors on secretion of plasmin, MMP-2, and TIMP-2 from PPAECs. Preincubation with wortmannin (10 nmol/L) or LY294002 (30 nmol/L) produced 50% to 60% suppression in Ang1*- and VEGF-induced plasmin secretion and 60% to 65% suppression in the Ang1*- and VEGF-induced MMP-2 secretion (Figures 6A and 6B). These results were confirmed by gelatin and fibrin zymography (Figures 7C and 7D). Interestingly, addition of wortmannin (10 nmol/L) or LY294002 (30 nmol/L) produced 34% suppression in the basal secretion of TIMP-2 (Figure 6C). Under these conditions, addition of Ang1* and VEGF produced a further 45% to 50% suppression in TIMP-2 secretion. These results suggest that activation of PI 3'-kinase may be involved in Ang1*- and VEGF-induced plasmin and MMP-2 secretions, but it may not be involved in suppression of TIMP-2 secretion.

₂-Antiplasmin, a Combination of TIMP-1 and TIMP-2, or PI 3'-Kinase Inhibitors Suppress Ang1*-Induced Sprouting Activity
Because Ang1* induced the secretion of plasmin, we examined the effect of ₂-antiplasmin (100 mU, added daily) on sprouting activity of cells grown on microcarrier beads in fibrin gels. Addition of ₂-antiplasmin produced 53% suppression of Ang1*-induced sprouting activity (Figures 8A and 8B). Given that the secretion ratio of MMPs to TIMPs was increased by Ang1*, we examined the effect of TIMPs on Ang1*-induced sprouting. Although the addition of either TIMP-1 (100 ng/mL) or TIMP-2 (100 ng/mL) did not produce a significant suppression of sprouting, a combination of TIMP-1 and TIMP-2 produced 36% suppression of Ang1*-induced sprouting activity (Figures 8A and 8B). Given that PI 3'-kinase inhibitors suppress migratory activity and secretion of plasmin and MMP-2, we examined the effect of PI 3'-kinase inhibitors on sprouting. Addition of wortmannin (10 nmol/L) or LY294002 (30 nmol/L) produced 68% or 61% suppression of Ang1*-induced sprouting activity, respectively (Figures 8A and 8B).

View larger version (57K): [in this window] [in a new window]   Figure 8. Effect of 2-antiplasmin, TIMPs, or PI 3'-kinase inhibitors on Ang1*-induced sprouting activity in PPAECs. Cells grown on microcarrier beads were placed in fibrin gels containing control buffer (C), 2-antiplasmin (AP, 100 mU), TIMP-1 (100 ng/mL) (T1), TIMP-2 (100 ng/mL) (T2), a combination of TIMP-1 (100 ng/mL) and TIMP-2 (100 ng/mL) (T1/2), wortmannin (W, 10 nmol/L), or LY294002 (L, 30 nmol/L) in the absence or presence of Ang1* (200 ng/mL). Beads were incubated with daily supplementation with the same amount of recombinant proteins. A, Representative phase-contrast photographs of sprouting activity. Note that fewer, shorter sprouts are formed in the presence of 2-antiplasmin, TIMP-1 plus TIMP-2 (TIMP1/2), or wortmannin than in control. Magnifications are x200. B, Quantification of the sprouting activities. Number of endothelial sprouts with length exceeding the diameter of the microcarrier bead (175 µm) was determined for every 50 microcarrier beads counted after 3 days. Data are mean±SD from 5 experiments. *P<0.05 vs control buffer only; #P<0.05 vs Ang1* only; P<0.05 vs T1/2 and Ang1*; +P<0.05 vs AP and Ang1*.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Endothelial cell sprouting is an initial step in angiogenesis and neovascularization.^{12 13} This process requires cell migration and invasion into the extracellular matrix beneath the basement membrane. During initial angiogenesis and vasculogenesis, a variety of growth factors and cytokines are upregulated and exert their functions through autocrine or paracrine actions. Of these, VEGF and Ang1 may be the key molecules, because their receptors are selectively located in endothelial cells.^{25 26} Recent reports indicate that transgenic overexpression or gene transfer of Ang1 increases vascularization.^{4 5} Thus, Ang1 is a reasonable candidate for therapeutic neovascularization for ischemic hearts or limbs. However, the exact mechanisms governing the increased vascularization with Ang1 overexpression are not yet known. Here, our findings explain how Ang1 induces sprouting in endothelial cells for increasing vascularization.

A member of the non–receptor protein-tyrosine kinases, p125^FAK, plays a key role in regulating dynamic changes in actin cytoskeleton organization during migration.¹⁵ Our results indicate that Ang1 induces tyrosine phosphorylation of p125^FAK and paxillin. These phosphorylation events take place rapidly, in a time- and concentration-dependent manner in endothelial cells. Thus, the migratory effect of Ang1 in endothelial cells may be mediated through actin cytoskeleton reorganization by tyrosine-phosphorylated p125^FAK and paxillin. We next investigated how Ang1 phosphorylated p125^FAK. Recent studies indicated that Tie2 activates PI 3'-kinase through an association with the p85 regulatory unit.^{27 28} Our results indicate that the PI 3'-kinase inhibitors completely inhibit Ang1-stimulated tyrosine phosphorylation of p125^FAK in endothelial cells and migration. This result suggests that PI 3'-kinase lies upstream in the signal transduction pathway linking Tie2 to the tyrosine phosphorylation of p125^FAK and migration. Therefore, we conclude that PI 3'-kinase activation is an essential intracellular element in Ang1-induced cell migration through tyrosine phosphorylation of p125^FAK.

To produce sprouting in response to Ang1 or VEGF stimulation in an in vitro fibrin gel, endothelial cells must secrete fibrinolytic enzymes. To date, the ability of endothelial cells to mediate fibrinolytic activity has been largely attributed to the powerful fibrinolysin, plasmin.²⁹ As we expected, Ang1 and VEGF induced plasmin secretion. However, a recent study identified MMP-dependent fibrinolytic pathways in the endothelial cells during neovascularization in fibrin gels.³⁰ However, our PPAECs secrete mainly MMP-2, which exhibits a lack of fibrinolytic activity.³⁰ Indeed, our fibrin zymography did not produce fibrinolytic bands where MMP-2 was active, whereas it produced strong fibrinolytic bands where plasmin was active. Our gelatin-zymographic assay reveals that Ang1, like VEGF, is a stimulant for secretion of proMMP-2. Although plenty of proMMP-2 is secreted and accumulated in the medium by Ang1 or VEGF stimulation, the conversion from proMMP-2 to active MMP-2 is not proportional. Cell membrane–associated processing with membrane type 1-MMP and TIMP-2 may be required for conversion to active MMP-2.³¹ Some larger (74 kDa) gelatinolytic bands of unknown nature are observed in the culture medium of PPAECs. They could be proMMP-2 bound with an unknown protein or unknown gelatinase. The balanced ratio between the levels of MMPs and TIMPs is a critical factor in regulating the breakdown of matrix proteins by MMPs.^{21 22} Our results indicate that TIMP-2 secretion is greater than TIMP-1 secretion in PPAECs. Ang1, like VEGF,³² decreases TIMP-2, but not TIMP-1, secretion. Therefore, the increased ratio between MMPs and TIMPs by Ang1 is favorable for the degradation of matrix proteins. Notably, our results indicate that activation of PI 3'-kinase could be involved in Ang1*- and VEGF-induced plasmin and MMP-2 secretions but not in TIMP-2 secretion. The mechanisms by which PI 3'-kinase is involved in Ang1*- and VEGF-induced plasmin and MMP-2 secretions will be examined in future studies.

Given that our sprouting activities were measured in fibrin gels, Ang1-induced plasmin secretion, rather than Ang1-induced MMP-2 secretion, could be a major determinant for sprouting. Consistent with this idea, addition of ₂-antiplasmin produced a more pronounced suppressive effect than combination of TIMP-1 and TIMP-2 on Ang1-induced sprouting activity. However, the suppressive effect of the combination of TIMP-1 and TIMP-2 was unexpected. Previous studies indicate that TIMPs have several other functions, including inhibition of basic fibroblast growth factor–induced endothelial cell proliferation and endothelial tube formation.²² Thus, the suppressive effects of TIMPs on Ang1-induced sprouting activity in endothelial cells will be examined in future studies. Given that PI 3'-kinase inhibitors suppressed Ang1*-induced migration and secretion of plasmin and MMP-2 in endothelial cells, PI 3'-kinase activation could be major intracellular mediator for sprouting. Consistent with this idea, addition of PI 3'-kinase inhibitors produced a marked and more pronounced suppressive effect than ₂-antiplasmin on Ang1-induced sprouting activity.

In summary, the present results explain how Ang1 induces sprouting in endothelial cells. Ang1 induces endothelial cell migration mediated through Tie2 receptor binding and PI 3'-kinase activation. The Ang1-induced migratory effect might be mediated through tyrosine phosphorylation of p125^FAK in a manner that requires PI 3'-kinase activity. Increased plasmin and MMP-2 secretion from endothelial cells by Ang1 is also an important determinant for inducing sprouting. These secretions are inhibited by PI 3'-kinase inhibitors. Taken together, Ang1-induced sprouting process in vivo may be accomplished by enhanced cytoskeletal changes and secretion of proteinases mainly mediated through intracellular PI 3'-kinase activation.

	Acknowledgments

 
This work was supported by the Creative Research Initiatives of the Korean Ministry of Science and Technology. We thank Peter C. Maisonpierre and George D. Yancopoulos (Regeneron Pharmaceuticals, Inc) for providing critical angiopoietins and Tie reagents.

Received February 9, 2000; accepted March 2, 2000.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor by secretion-trap expression cloning. Cell. 1996;87:1161–1169.[Medline] [Order article via Infotrieve]
2. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopioetin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60.[Abstract/Free Full Text]
3. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171–1180.[Medline] [Order article via Infotrieve]
4. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282:468–471.[Abstract/Free Full Text]
5. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation. 1998;98:2081–2087.[Abstract/Free Full Text]
6. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U, Risau W. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol. 1998;8:529–532.[Medline] [Order article via Infotrieve]
7. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem. 1998;273:18514–18521.[Abstract/Free Full Text]
8. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest. 1999;79:213–223.[Medline] [Order article via Infotrieve]
9. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vascular cooption, regression and growth by tumors involving angiopoietins and VEGF. Science. 1999;284:1994–1998.[Abstract/Free Full Text]
10. Kim I, Kim HG, So J-N, Kim JH, Kwak HJ, Koh GY. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ Res. 2000;86:24–29.[Abstract/Free Full Text]
11. Kim I, Moon S-O, Koh KN, Kim H, Uhm CS, Kwak HJ, Kim NG, Koh GY. Molecular cloning, expression, and characterization of angiopoietin-related protein. J Biol Chem. 1999;274:26523–26528.[Abstract/Free Full Text]
12. Klagsburn M, D’Amore P. Regulators of angiogenesis. Annu Rev Physiol. 1991;53:217–239.[Medline] [Order article via Infotrieve]
13. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674.[Medline] [Order article via Infotrieve]
14. Stossel TP. On the crawling of animal cells. Science. 1993;260:223–231.
15. Schaller MD, Parsons JT. Focal adhesion kinase and associated proteins. Curr Opin Cell Biol. 1994;6:705–710.[Medline] [Order article via Infotrieve]
16. Abedi H, Zachary I. Signaling mechanisms in the regulation of vascular cell migration. Cardiovasc Res. 1995;30:544–556.[Medline] [Order article via Infotrieve]
17. Tachibana K, Sato T, D’Avirro N, Morimoto C. Direct association of pp125FAK with paxillin, the focal adhesion-targeting mechanism of pp125FAK. J Exp Med. 1995;182:1089–1099.[Abstract/Free Full Text]
18. Pepper JS, Montesano R, Mandriota SJ, Orci L, Vassalli JD. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996;49:138–162.[Medline] [Order article via Infotrieve]
19. Grant DS, Kleinman HK. Regulation of capillary formation by laminin and other components of the extracellular matrix. EXS. 1997;79:317–334.[Medline] [Order article via Infotrieve]
20. Frederick J, Woessner Jr. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinase. London, England: Academic Press; 1998:1–14.
21. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274:21491–21494.[Free Full Text]
22. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation, and biologic functions. Eur J Cell Biol. 1997;74:111–122.[Medline] [Order article via Infotrieve]
23. Rosen EM, Meromsky L, Setter E, Vinter DW, Goldberg I. Quantitation of cytokine-stimulated migration of endothelium and epithelium by a new assay using microcarrier beads. Exp Cell Res. 1990;186:22–31.[Medline] [Order article via Infotrieve]
24. Kleiner DE Jr, Margulis IMK, Stetler-Stevenson WG. Proteinase assays/zymography. In: Doyle A, Griffiths JB, Newell DG, eds. Cell and Tissue Culture: Laboratory Procedures. W Sussex, UK: John Wiley and Sons, Ltd; 1998:5A:7.1–7.8.
25. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol. 1999;9:211–220.[Medline] [Order article via Infotrieve]
26. Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48–50.[Free Full Text]
27. Kondos CD, Stauffer TP, Yang WP, York JD, Huang L, Blanar MA, Meyer T, Peters KG. Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol Cell Biol. 1998;18:4131–4140.[Abstract/Free Full Text]
28. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K, Dumont DJ. Identification of Tek/Tie2 binding protein. J Biol Chem. 1999;274:30896–30905.[Abstract/Free Full Text]
29. Hajjar KA. Changing concepts in fibrinolysis. Curr Opin Hematol. 1995;2:345–350.[Medline] [Order article via Infotrieve]
30. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 1998;95:365–377.[Medline] [Order article via Infotrieve]
31. Yu AE, Murphy AN, Stetler-Stevenson WG. 72-kDa gelatinase (gelatinase A): structure, activation, regulation, and substrate specificity. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinase. London, England: Academic Press; 1998:85–113.
32. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998;55:29–42.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				R. Zhande, S. M. Dauphinee, J. A. Thomas, M. Yamamoto, S. Akira, and A. Karsan FADD Negatively Regulates Lipopolysaccharide Signaling by Impairing Interleukin-1 Receptor-Associated Kinase 1-MyD88 Interaction Mol. Cell. Biol., November 1, 2007; 27(21): 7394 - 7404. [Abstract] [Full Text] [PDF]

				H. T. Yuan, S. Venkatesha, B. Chan, U. Deutsch, T. Mammoto, V. P. Sukhatme, A. S. Woolf, and S. A. Karumanchi Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival FASEB J, October 1, 2007; 21(12): 3171 - 3183. [Abstract] [Full Text] [PDF]

				R. Harfouche and S. N. A. Hussain Signaling and regulation of endothelial cell survival by angiopoietin-2 Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1635 - H1645. [Abstract] [Full Text] [PDF]

				X.-B. Liang, L.-J. Ma, T. Naito, Y. Wang, M. Madaio, R. Zent, A. Pozzi, and A. B. Fogo Angiotensin Type 1 Receptor Blocker Restores Podocyte Potential to Promote Glomerular Endothelial Cell Growth J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1886 - 1895. [Abstract] [Full Text] [PDF]

				Y. M. Kim, K. E. Kim, G. Y. Koh, Y.-S. Ho, and K.-J. Lee Hydrogen peroxide produced by angiopoietin-1 mediates angiogenesis. Cancer Res., June 15, 2006; 66(12): 6167 - 6174. [Abstract] [Full Text] [PDF]

				B. N. Feltis, D. Wignarajah, L. Zheng, C. Ward, D. Reid, R. Harding, and E. H. Walters Increased Vascular Endothelial Growth Factor and Receptors: Relationship to Angiogenesis in Asthma Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1201 - 1207. [Abstract] [Full Text] [PDF]

				N. P.J. Brindle, P. Saharinen, and K. Alitalo Signaling and Functions of Angiopoietin-1 in Vascular Protection Circ. Res., April 28, 2006; 98(8): 1014 - 1023. [Abstract] [Full Text] [PDF]

				R. Koshida, P. Rocic, S. Saito, T. Kiyooka, C. Zhang, and W. M. Chilian Role of Focal Adhesion Kinase in Flow-Induced Dilation of Coronary Arterioles Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2548 - 2553. [Abstract] [Full Text] [PDF]

				L. Kugathasan, A. E. Dutly, Y. D. Zhao, Y. Deng, M. J. Robb, S. Keshavjee, and D. J. Stewart Role of Angiopoietin-1 in Experimental and Human Pulmonary Arterial Hypertension Chest, December 1, 2005; 128(6_suppl): 633S - 642S. [Abstract] [Full Text] [PDF]

				T. Murakami, H. Takagi, K. Suzuma, I. Suzuma, H. Ohashi, D. Watanabe, T. Ojima, E. Suganami, M. Kurimoto, H. Kaneto, et al. Angiopoietin-1 Attenuates H2O2-induced SEK1/JNK Phosphorylation through the Phosphatidylinositol 3-Kinase/Akt Pathway in Vascular Endothelial Cells J. Biol. Chem., September 9, 2005; 280(36): 31841 - 31849. [Abstract] [Full Text] [PDF]

				T.-L. Shen, A. Y.-J. Park, A. Alcaraz, X. Peng, I. Jang, P. Koni, R. A. Flavell, H. Gu, and J.-L. Guan Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis J. Cell Biol., June 20, 2005; 169(6): 941 - 952. [Abstract] [Full Text] [PDF]

				T. Morisada, Y. Oike, Y. Yamada, T. Urano, M. Akao, Y. Kubota, H. Maekawa, Y. Kimura, M. Ohmura, T. Miyamoto, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation Blood, June 15, 2005; 105(12): 4649 - 4656. [Abstract] [Full Text] [PDF]

				C. C. Weber, H. Cai, M. Ehrbar, H. Kubota, G. Martiny-Baron, W. Weber, V. Djonov, E. Weber, A. S. Mallik, M. Fussenegger, et al. Effects of Protein and Gene Transfer of the Angiopoietin-1 Fibrinogen-like Receptor-binding Domain on Endothelial and Vessel Organization J. Biol. Chem., June 10, 2005; 280(23): 22445 - 22453. [Abstract] [Full Text] [PDF]

				C. Schlueter, H. Weber, B. Meyer, P. Rogalla, K. Roser, S. Hauke, and J. Bullerdiek Angiogenetic Signaling through Hypoxia: HMGB1: An Angiogenetic Switch Molecule Am. J. Pathol., April 1, 2005; 166(4): 1259 - 1263. [Abstract] [Full Text] [PDF]

				D. Voskas, N. Jones, P. Van Slyke, C. Sturk, W. Chang, A. Haninec, Y. O. Babichev, J. Tran, Z. Master, S. Chen, et al. A Cyclosporine-Sensitive Psoriasis-Like Disease Produced in Tie2 Transgenic Mice Am. J. Pathol., March 1, 2005; 166(3): 843 - 855. [Abstract] [Full Text] [PDF]

				L. J. Kornberg, L. C. Shaw, P. E. Spoerri, S. Caballero, and M. B. Grant Focal Adhesion Kinase Overexpression Induces Enhanced Pathological Retinal Angiogenesis Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4463 - 4469. [Abstract] [Full Text] [PDF]

				X. Peng, H. Ueda, H. Zhou, T. Stokol, T.-L. Shen, A. Alcaraz, T. Nagy, J.-D. Vassalli, and J.-L. Guan Overexpression of focal adhesion kinase in vascular endothelial cells promotes angiogenesis in transgenic mice Cardiovasc Res, December 1, 2004; 64(3): 421 - 430. [Abstract] [Full Text] [PDF]

				N. L. Ward, A. L. Haninec, P. Van Slyke, J. G. Sled, C. Sturk, R. M. Henkelman, I. R. Wanless, and D. J. Dumont Angiopoietin-1 Causes Reversible Degradation of the Portal Microcirculation in Mice: Implications for Treatment of Liver Disease Am. J. Pathol., September 1, 2004; 165(3): 889 - 899. [Abstract] [Full Text] [PDF]

				H. J. LEE, C.-H. CHO, S.-J. HWANG, H.-H. CHOI, K.-T. KIM, S. Y. AHN, J.-H. KIM, J.-L. OH, G. M. LEE, and G. Y. KOH Biological characterization of angiopoietin-3 and angiopoietin-4 FASEB J, August 1, 2004; 18(11): 1200 - 1208. [Abstract] [Full Text] [PDF]